Evaluation of Patiromer in Heart Failure Patients
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of Patiromer in Heart Failure Patients
Sponsor: Medpace, Inc.
Listed as NCT00868439, this PHASE2 trial focuses on Heart Failure and Hyperkalemia and remains completed. Sponsored by Medpace, Inc., it has been updated 8 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medpace, Inc.
- Relypsa, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barnaul, Russia, Brno, Czechia, Buffalo, United States, Columbus, United States, Dallas, United States, Dnipropetrovsk, Ukraine, Göttingen, Germany, Heidelberg, Germany, Kemerovo, Russia, Kharkiv, Ukraine and 12 more location s